The discovery of fingolimod (FTY720/Gilenya; Novartis), an orally active immunomodulatory
drug, has opened up new approaches to the treatment of multiple sclerosis, the most …

A 37-year-old man with multiple sclerosis has recurrent disease activity despite several
previous therapies. Treatment with fingolimod is recommended. Fingolimod blocks the …

Objective: To assess long-term safety and efficacy of fingolimod in patients with relapsing-
remitting multiple sclerosis (RRMS). Methods: Patients completing FTY720 Research …

Objective The 12-month (M), phase 3, double-blind, randomised TRANSFORMS study
demonstrated significant benefits of fingolimod 0.5 or 1.25 mg over interferon β-1a (IFNβ-1a) …

Background In a 12-month phase 3 study in patients with relapsing-remitting multiple
sclerosis (RRMS), TRANSFORMS, fingolimod showed greater efficacy on relapse rates and …

Multiple sclerosis (MS) is an immune mediated disease of the central nervous system (CNS)
and the leading cause of non-traumatic disability among young and middle-aged adults in …

Purpose Interferon injectables and glatiramer acetate have served as the primary disease-
modifying treatments for multiple sclerosis (MS) since their introduction in the 1990s and are …

Background Fingolimod 0· 5 mg once daily is approved for treatment of relapsing multiple
sclerosis (MS). In the phase 3, 2-year FREEDOMS (FTY720 Research Evaluating Effects of …

Sphingolipids are a fascinating class of signaling molecules derived from the membrane
lipid sphingomyelin. They show abundant expression in the brain. Complex sphingolipids …

Objective: To report outcomes of pregnancies that occurred during the fingolimod clinical
development program. Methods: Pregnancy outcomes from phase II, phase III, and phase IV …